Topoisomerase Type II Structures

Topoisomerase Type II Structures. Comparison & Implications of the ’07 Berger & Dong Model. Topoisomerase: what is it?. Enzymes within cells that remove excessive supercoiling—and thereby torsional stress—while maintaining sufficient supercoiling to ensure a stable compact genome.

Share Presentation
Embed Code
Link
Download Presentation

gage-barnes

gage-barnes + Follow

Download Presentation

Topoisomerase Type II Structures

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

Presentation Transcript

  1. Topoisomerase Type II Structures Comparison & Implications of the ’07 Berger & Dong Model
  2. Topoisomerase: what is it? • Enzymes within cells that remove excessive supercoiling—and thereby torsional stress—while maintaining sufficient supercoiling to ensure a stable compact genome. • These enzymes are apparent in every cellular function involved with DNA—transcription, replication, recombination, and chromosome separation. • The enzymes complete their job in any of the above function by cleavage; that is, cutting. • Type I topoisomerase cut only 1 strand of DNA, Type II topoisomerase cut both (2) strands of DNA.
  3. Type I Isomerase lA: links to 5’-phosphate terminus, relaxes negatively supercoiled DNA, introduces transient breaks in ss region of DNA IB: links 3’ terminus covalently to tyrosol group, relaxes both negatively and positively supercoiled DNA, segment can rotate with respect to protein to relieve torsional stress Neither require ATP energy Both cut only 1 strand of DNA Type II Isomerase IIA: found in eukaryotes, highly expressed in cancerous cells IIB: structurally and biochemically distinct from Type IIA, found in archaea and some higher plants Both require ATP energy to activate Both perform a double-stranded cut of DNA What’s Our Type?
  4. Type I Isomerase lA: links to 5’-phosphate terminus, relaxes negatively supercoiled DNA, introduces transient breaks in ss region of DNA IB: links 3’ terminus covalently to tyrosol group, relaxes both negatively and positively supercoiled DNA, segment can rotate with respect to protein to relieve torsional stress Neither require ATP energy Both cut only 1 strand of DNA Type II Isomerase IIA: found in eukaryotes, highly expressed in cancerous cells IIB: structurally and biochemically distinct from Type IIA, found in archaea and some higher plants Both require ATP energy to activate Both perform a double-stranded cut of DNA What’s Our Type?
  5. Topoisomerase Type IIA • Mechanism: A two-gate structure, Type II topoisomerases work by cleaving and opening one DNA duplex, passing a second duplex through the opening, and then resealing the break.
  6. Topoisomerase Type IIA • Function: Type II topoisomerase performs a cycle of DNA cleavage, transport, and religation (coupled with ATP binding and hydrolysis) to preserve the topological invariant of the DNA • That is, it relaxes positively and negatively charged supercoiled DNA and performs cantenations/decantenations to prevent torsional stress and keep the cell’s compact genetic structure • This is an essential function for cell functionality and survival, and so all organisms have at least one type of Type II topoisomerase!
  7. Berger & Dong 2007 Model Summary Conclusions Impact Limitations Comparison to Previous Models Berger et al Model 1996 Rybenkov et al Model 1997 Vologodskii et al Model 2001
  8. Berger and Dong 2007 Model Summary • The molecular understanding of DNA binding to Topo II was examined • Crystallization of the Topo II-DNA complex was performed • Crystallography determines the arrangement of atoms in solids
  9. Berger & Dong 2007 Model Summary Conclusions Impact Limitations Comparison to Previous Models Berger et al Model 1996 Rybenkov et al Model 1997 Vologodskii et al Model 2001
  10. Berger and Dong 2007 Model Conclusions • Upon binding, Topo II distorts the DNA at ~150 degree global angle • The mechanism of this bend very similar to remodeling proteins • Along with the change in DNA’s conformation, Topo II undergoes a conformational change • This change forms a catalytic site for the ‘cutting’ reaction Change in Top2’s conformation (shape) Bending of DNA
  11. Berger & Dong 2007 Model Summary Conclusions Impact Limitations Comparison to Previous Models Berger et al Model 1996 Rybenkov et al Model 1997 Vologodskii et al Model 2001
  12. Berger and Dong 2007 Model • The researchers concluded that their findings: • Corroborated previous biochemical findings about Topo II • Established the structure as mechanism intermediate • Discovery of DNA cleavage controls • ***Control of DNA topology • Is Topo II attracted to curvature OR does it cause the curvature? (Which came first, the chicken or the egg?) • Question is resolved….Topo II CAUSES curvature! (via bending) • This bending provides a means to decatenation and relaxation • Preferred binding sites @ highly curved DNA crossovers and loops in vivo probably arise from intrinsic deforms DNA
  13. Berger & Dong 2007 Model Summary Conclusions Impact Limitations Comparison to Previous Models Berger et al Model 1996 Rybenkov et al Model 1997 Vologodskii et al Model 2001
  14. Berger and Dong 2007 Model Limitations • Only a portion of Topo II was examined • Fragment used was ~720 aa long (residues 408-1177) • Experiment performed in vitro • Model organism used was S. cerevisiae, or yeast (is structure/binding/bending conserved with other organisms?
  15. Berger & Dong 2007 Model Summary Conclusions Impact Limitations Comparison to Previous Models Berger et al Model 1996 Rybenkov et al Model 1997 Vologodskii et al Model 2001
  16. Berger Model 1996 1996 cartoon • One of the researchers of Dong/Berger model published a report on the Structure and Mechanism of Topo II 12 years ago • The Topo II examined was also S. cerevisiae of similar size to 2007 model • In 1996, researchers thought conformation changes occurred after passage of T-segment, not upon binding of G-segment • Bending of DNA upon binding with Topo II was not detected 2007 cartoon
  17. Rybenkov Model 1997 Top2 bound to crossover • This study didn’t specifically look at the structure of Topo II, but it examined implications of its mechanism • Rybenkov et al concluded that Topo II doesn’t simply catalyze the passing of one DNA strand through another, changing its local conformation and topology, but it controls the global property of DNA as well • Suggested Topo II catalyzed the passage of one strand through another if resulting crossing angles were favorable • Suggested Topo II shortened DNA • Topo II binds three (3) DNA segments (crossover complex)
  18. Vologodskii Model 2001 Simulation of DNA • This study attempted to use its model to explain previous experimental data • Computer Analysis of enzyme performed • Discrete worm-like chain • Monte Carlo procedure simulated possible DNA conformations • Found that simplification of DNA topology by Topo II not possible without distortion of DNA • Suggested that Topo II create asymmetry in DNA upon binding DNA distortion by Topo II
  19. Applications of the Berger & Dong 2007 Model Summary of Topoisomerase Type II pharmaceuticals Existing limitations with current Topoisomerase Type II-focused medications Increasing drug efficiency with Berger & Dong’s current Topoisomerase Type II model
  20. Pharmaceuticals Summary • Mammalian type II topoisomerases are targets of anti-tumor drug classes - aminoacridines, anthracenediones, ellipticines, and epipodophyllotoxins. - many of them interact with DNA by an intercalative mode • Bacterial type II toposiomerases are targets of antibacterial gents - quinolones and flouroquinolones.
  21. DNA intercalators are used in chemotherapeutic treatment to inhibit DNA replication in rapidly growing cancer cells. Ethidiumintercalated between two adenine-uracil base pairs.
  22. How does drug work on DNA? • The drug ,localized precisely at the site of DNA cleavage, prevents topoisomerase from rejoining DNA breaks. • Cleavage complexes themselves are not sufficient to cause cell death. • Active cellular processes (transcription/replication) are necessary to transform cleavage complexes into cytotoxic lesions
  23. Complex by protein-denaturant treatment-NaDodSO4/alkali • After binding to one segment of duplex DNA, a type II topoisomerase cleaves the duplex with a four-base stagger. Model for the initial steps in the topoisomerase Il-catalyzedDNA strand-passing reaction. (A) Unbound topoisomerase.(B) Noncleavable complex. (C) Cleavable complex.
  24. Current Limitations • Multi-drug resistance - Altered topoisomerase II complex activities - results in decreased ability to form a stable ternary complex - current measurements of topoisomerase II not reveal the relevant qualitative change
  25. Current Limitations • Unrecognized cofactors may influence topoisomerase II activity and confound analyses. • Drug-topoisomerase II interactions and the precise defects in cells( altered activity) are not understood completely.
  26. Pharmaceutical Impact • With the current Berger and Dong model for Topoisomerase Type II, we can: • Examine complex DNA and see if its geometry is changed by experimental drugs • Test inhibitors for Topoisomerase Type II to prevent DNA bending and kill the cell • Prevent rigidity in Topoisomerase Type II treatments due to built-up resistance
  27. Further Research
  28. Future Research • Multicellular Confirmation • Is Berger and Dong’s model conserved when the experiment is repeated on multicellular organisms • Enzyme Shift • Following Berger and Dong’s model bending DNA, does the enzyme undergo another conformational change prior to cutting the DNA
  29. Future Research • Chemical basis of DNA cleavage • Benefits of unidirectional transport – not understood • Visualization of DNA cleavage
  30. References - “Structure and mechanism of DNA topoisomerase II” + James Berger & Ken Dong; Nature, Vol. 379, Jan. 1996, pp. 225 – 232 - “Simplification of DNA Topology Below Equilibrium Values by Type II Topoisomerases” + Valentin Rybenkov et al; Science; Vol. 277; Aug. 1997; pp. 690 – 693 - “Mechanism of topology simplification by type II DNA topoisomers” + Alexander Vologodskii et al; PNAS; Vol. 98 No. 6; Mar. 2001; pp. 3045 – 3049 - “An Antitumor Drug-Induced Topoisomerase Cleavage Complex Blocks a Baccteriophage T4 Replication Fork in Vivo” + George Hong & Kenneth Kreuzer; Molecular and Cellular Biology; Vol 20 No. 2; Jan. 2000; pp.594-603 • “Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: lingand-induced DNA—protein crosslinking and responses to topoisomerase poisons + Paul J. Smith et al; Carcinogenesis; Vol 11 No. 4; pp.659-665 • “Multidrug Resistance Associated With Altered Topoisomerase II Activity—Topoisomerases II as Targets for Rational Drug Design” + Kenneth Cowan & Charles Marrow; National Cancer Institute; February 28, 1990. • “Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4’-(9-acridinylamino)-methanesulfon-m-anisidide” + Eric M. Nelson et al; Proc. Natl. Acd. Sci. USA; Vol 81; Mar 1984; pp.1361-1365 • “Design of DNA Intercalators To Overcome Topoisomerase II-Mediated Multidrug Resistance” + Bruce C. Baguley et al; Journal of the National Cancer Institute; Vol 82; Mar. 1990; pp.398-402

Structures II

Structures II

Structures II. Soon Tee Teoh CS 49C. Initializing an array. A variable can be initialized when it is declared. Likewise, an array can be initialized. int x = 5; int arr = < 3, 2, 5>;. Initializing a struct. Likewise, a struct can also be initialized.

223 views • 9 slides

Topoisomerase-II  a Predictive Molecular Marker in Breast Cancer:

Topoisomerase-II  a Predictive Molecular Marker in Breast Cancer:

Topoisomerase-II  a Predictive Molecular Marker in Breast Cancer:. Konecny G, Jakobson K, Pegram M, Pauletti G, Dandekar U, Morisson J Ramos L. He-Jing Wang, Seelig S, and Slamon DJ . University of California, Los Angeles Vysis Inc., Downers Grove, Illinois.

466 views • 32 slides

TYPE I AND TYPE II CIDH

TYPE I AND TYPE II CIDH

TYPE I AND TYPE II CIDH. The Good, the Bad, and the Ugly 2 May 2008 Sacramento, CA Alan Macnab. OUTLINE. Installation Issues Rebar Spacing Flow Research Caltrans Rebar Design Concrete Cover Type I issues Type II Issues Other States Solutions Recommendations.

899 views • 29 slides

Type Systems and Structures

Type Systems and Structures

Type Systems and Structures. Programming Language Principles Lecture 22. Prepared by Manuel E. Bermúdez, Ph.D. Associate Professor University of Florida. Data Types. Most PLs have them. Two purposes: Provide context for operations, e.g. a+b (ints or floats). In Java,

940 views • 83 slides

Type II Diabetes

Type II Diabetes

Type II Diabetes. Gil C. Grimes, MD September 2006. Objectives. Define Diagnosis of Diabetes Describe Pathogenesis Describe risk factors for Type II diabetes Outline complications Delineate options for therapy. Definition. American Diabetes Association

1.08k views • 78 slides

Type I and Type II Errors

Type I and Type II Errors

Type I and Type II Errors. Ms. Betts Chapter 9 Quiz. Justice System . Warm-Up: Read “ Making Mistakes in the Justice System.” When you are done reading, raise your hand for a questions sheet. Hypothesis Testing. In each test, there are two possible decisions:

455 views • 19 slides

Type II

Type II

Type II. The article addresses major failings of Reconstruction. Describe one of the issues and how efforts to address the issue failed during Reconstruction. The Challenge of Reconstruction (1865-1877). I. Two Fundamental Problems. How to deal with the defeated South

298 views • 13 slides

Type II Error

Type II Error

Type II Error. The probability of making a Type II error is denoted as b . The actual value of b is unknown, we can only calculate possible values for b . Type II Error.

478 views • 30 slides

Type I & Type II errors

Type I & Type II errors

Type I & Type II errors. Brian Yuen 18 June 2013. Definition of Type I error ( α ). Concluded a statistical significant effect size from the sample when this does not exist in the whole population (H 0 is true) Reject the null hypothesis (H 0 ) when it is true False positive result

446 views • 10 slides

BE 10988 : An Inhibitor of DNA –Topoisomerase II

BE 10988 : An Inhibitor of DNA –Topoisomerase II

BE 10988 : An Inhibitor of DNA –Topoisomerase II. Indira Thapa November 24, 2005. DNA. Double helical structure Store genetic information Uncontrolled cell growth-Cancer. Sugar-phosphate backbone Bases H-bonds. DNA - A Molecular Target for Cancer Therapeutics. Protein-DNA

1.12k views • 43 slides

Type II

Type II

Type II. Cytotoxic hypersensitivity Reaction time is minutes to hours mediated by antibodies of IgM or IgG class and complement Phagocytes and NK cells may also play a role (ADCC). Diagnostic tests include detection of

485 views • 29 slides

Type I and Type II Error

Type I and Type II Error

Type I and Type II Error. AP Stat Review, April 18, 2009. Fundamental Outcomes in Hypothesis Tests. As we all (hopefully) remember, results of hypothesis tests fall into one of four scenarios:. Type I Error. OK. OK. Type II Error. Jury Trial vs. Hypothesis Test. Assumption. Defendant is

324 views • 17 slides

TYPE II

TYPE II

HAND OPENING. a) LF – Delay (IPJ-MCPJ) [% dur]. b) TH – Delay (IPJ-MCPJ) [% dur]. p <0.05. 50. 50. 40. 40. *. *. 30. 30. 20. 20. 10. 10. CO  SD. **. ***. 0. 0. TYPE I I - I II. TYPE 0 , I, MIX. -10. -10. TYPE 0. TYPE II. -20. -20. TYPE II I. TYPE I. -30. -30.

127 views • 1 slides

DIABETES TYPE II

DIABETES TYPE II

DIABETES TYPE II. ActoplusMet GROUP 1. Physiology of the Condition. a number of metabolic disorders with elevated blood glucose levels or Hyperglycemia. These disorders usually result from defects in Insulin secretion, Insulin action, or both. Physiology of the Condition.

336 views • 25 slides

Type Inference II

Type Inference II

Type Inference II. David Walker CS 510. ML-style Polymorphism. 2 characteristics: prenex (let) polymorphism let f : all [a,b,c].t = . in e polymorphic quantifiers appear in outermost positions polymorphic values can’t be arguments/results of functions, can’t be stored

238 views • 11 slides

Structures - Part II aggregate operations arrays of type struct nested structures

Structures - Part II aggregate operations arrays of type struct nested structures

Structures - Part II aggregate operations arrays of type struct nested structures compared to classes. Aggregate Operations. Operation Arrays Structs I/O No ( except strings ) No Assignment No Yes Arithmetic No No Comparison No No

362 views • 21 slides

Type II Diabetes

Type II Diabetes

Type II Diabetes. G. Michael Allan Associate Professor, Family Med, U of A. Conflict of Interest Disclosure. Family Doctor & Academic Pay from University and Alberta Health Research and Speaking Fees Non-Profit Sources (CFPC, ENPCN, TOP, etc) No funding from Industry. Objectives.

659 views • 55 slides

Type Inference II

Type Inference II

Type Inference II. David Walker COS 441. Type Inference. Goal: Given unannotated program, find its type or report it does not type check Overview: generate type constraints (equations) from unannotated programs solve equations. Constraint Generation.

435 views • 27 slides

Type II Projectiles

Type II Projectiles

Type II Projectiles. Type II Projectile Motion. Projectile motion in which launch angle is above the horizon and the projectile lands at the same altitude as it was launched.

251 views • 13 slides

Type II Diabetes

Type II Diabetes

Type II Diabetes. Matthew Love, M.D. Case 1. Fred Banting, a 52 year-old man, complains of polyuria and polydypsia for three weeks. On questioning, he also admits to dizziness on standing. On exam, his BP is 135/80, Pulse 95. He is 5’8” tall, weighs 220# and has acanthosis nigricans.

662 views • 54 slides

Type II

Type II

Type II. What is Type II ?. Binary (Metal + Non-metal) Ionic Compound Metal DOES NOT have a fixed charge. Example: Most transition metals (except Ag + , Zn 2+ ,Cd 2+ ) Mn 3+ or Mn 7+ Cr 2+ or Cr 7+. Rules for Naming Type II. Cation (metal) is named first

206 views • 9 slides

Diabetes Type II

Diabetes Type II

Diabetes Type II. Bryce P. Rishi S. Jay S. What is Diabetes II?. Diabetes is a disease that occurs when a person's body does not make enough insulin or, can't use insulin properly. It is mostly a lifestyle disease for people that are obese. It also can be hereditary.

396 views • 11 slides